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To evaluate cervicovaginal fluid quantitative fetal fibronectin, measured by a bedside 
analyser, to predict spontaneous preterm birth in twin pregnancy before 30 weeks of 
gestation. 
 
Materials and Methods 
In a prospective cohort study, we studied the accuracy of quantitative fetal fibronectin 
measured between 18 and 27+6 weeks of gestation in high risk asymptomatic women with 
twin pregnancies, to predict spontaneous preterm birth before 30 weeks of gestation.  
Predefined fetal fibronectin thresholds were greater than or equal to 10, greater than or equal 
to 50, and greater than or equal to 200 ng/ml.  Predictive statistics were also calculated to 
evaluate accuracy of ‘early’ tests, performed between 18 and 21+6 weeks  and ‘standard’ tests 
performed between 22+0 and 27+6 weeks of gestation  in the same cohort. Subgroup analysis 
was performed according to cervical length measurement.  In addition, we compared 
accuracy of prediction with quantitative fetal fibronectin measured during the standard test 
period in asymptomatic twin pregnancy with no additional risk factors, to twin pregnancies 
with one or more additional risk factors for spontaneous preterm birth.   
 
Results 
Of 130 eligible women identified with quantitative fetal fibronectin tests undertaken during 
the standard testing period, 9% delivered before 30 weeks of gestation.  Quantitative fetal 
fibronectin was significantly related to outcome before 30/40 (ROC curves of 0.8 (CI 0.7 to 
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1).  Early tests were not significantly predictive; ROC area 0.53 (CI 0.29 to 0.81)     There 
was a trend towards better predictive accuracy when one or more additional risk factors for 
spontaneous preterm birth, or cervical length was considered. 
 
Conclusions 
Quantitative fetal fibronectin measured from 22 to 27+6 weeks of gestation accurately 
predicts spontaneous preterm birth at <30 weeks of gestation.  Tests undertaken earlier are of 
limited value.  Consideration of cervical length, or prior history in addition to qfFN 
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Abbreviations 
CL Cervical Length 
fFN fetal fibronectin 
PPROM Preterm prelabour rupture of membranes 
QfFN Quantitative fetal fibronectin 
sPTB Spontaneous Preterm Birth 
 
Key Message  
Quantitative fetal fibronectin can be used to accurately predict preterm birth less than 30 
weeks’ gestation in twin pregnancy, in women who are asymptomatic of threatened preterm 














Twin pregnancies are increasing.  There was a 60% increase in the UK between 1980 and 
2009, with a further 20% rise between 2009 - 2015, mainly related to assisted reproductive 
technology and older maternal age at conception.(1) Preterm birth is the commonest morbidity 
associated with multiple pregnancy, 50% of twin pregnancies are preterm with 10% delivered 
at <32 weeks’, (2) which puts the neonate at greater risk of respiratory distress syndrome, 
sepsis, cerebral palsy, cognitive defects and neonatal death. (3) 
 
Twins are a powerful risk factor for preterm birth.  There is little research on how established 
risk factors for singleton pregnancy, including prior spontaneous preterm birth (sPTB) or 
preterm prelabour rupture of membranes (PPROM), previous late miscarriage (16-23 +6), and 
previous cervical surgery (Loop electrosurgical excision procedure, LEEP or cone biopsy), 
interact with twin pregnancy.   
 
The pathophysiology of sPTB in multiple pregnancy is related to myometrial stretch 
triggering prostaglandin release, upregulation of oxytocin receptors with increased 
myometrial contractility, (4) which may be different from singleton pregnancy. Prediction of 
sPTB in twin pregnancy with fetal fibronectin (fFN) and cervical length measurement may 
therefore differ.  
 
fFN is a glycoprotein located in the amniotic membranes.  Its presence in cervicovaginal 
secretions suggests disruption of the membranes.  Formerly a qualitative test with a positive/ 
negative result using a 50ng/ml threshold, it is now possible to establish the concentration of 
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fFN (qfFN) enabling more accurate prediction of preterm birth in symptomatic (5) and 
asymptomatic (6) singleton pregnancies.  In asymptomatic singleton pregnancies the standard 
testing window is 22 to 27+6 weeks’, although it has recently been shown that accurate 
prediction can be derived from 18 weeks’. (7) Qualitative fFN has been evaluated and found 
to be effective in symptomatic (8) and asymptomatic twin pregnancies, (9), (10) and can be used 
to help differentiate between women with a short cervix on ultrasonic cervical length (CL) 
measurement. (11)  
 
Given increasing rates of multiple pregnancy, there remains an urgent need to optimise 
prediction of sPTB to avoid overtreatment of women with costly drugs and unnecessary 
admission to maternal and neonatal units. Therefore, this study aims to evaluate qfFN for 
prediction of sPTB in asymptomatic women with twin pregnancy, across the detectable range 
to define its potential value. 
 
Materials and Methods 
 
This was a secondary analysis of the EQUIPP Study (Evaluation of a Quantitative Instrument 
for Prediction of Preterm Birth, EQUIPP), a prospective masked observational study of 1448 
high-risk asymptomatic women who underwent qfFN testing between 22+0– 27+6 weeks’ 
gestation at 5 UK teaching hospitals’  . (6) All women with twin pregnancies regardless of  
risk factors for sPTB who had a qfFN sample taken between 18 and 27+6 weeks of gestation, 
and did not have symptoms of threatened preterm labour were eligible for inclusion in the 
analysis.  Samples from women who reported prior sexual intercourse (within 24 hours) or 
frank bleeding visible on the swab were excluded as these are contraindications to using fetal 
fibronectin test. (12)   
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During speculum examination, a polyester swab was inserted into the posterior fornix of the 
vagina and rotated for 10 seconds to collect a sample of cervicovaginal fluid.  The swab was 
immediately placed into the test buffer solution and analysed.  One aliquot (200 microlitres) 
of the sample was analysed using the quantitative Rapid fFN 10Q analyser (Hologic, 
Marlborough, MA, USA) according to manufacturers’ instructions.  All clinicians received 
training to use the analysers.  Based on our previous research (6) test thresholds of 10, 50 and 
200ng/ml were predefined before the study data analysis.  Following the swab, CL 
measurement (mm) by transvaginal ultrasonography was performed by trained staff and the 
shortest of three values used in the analysis.  Clinicians were made aware of the categoric TLi 
IQ (Hologic, Marlborough, MA, USA) result (positive/negative), but both patient and clinician 
remained blinded to 10Q result until after delivery ( a random result code generated by 
analyser), as per EQUIPP protocol.  Women were managed in the clinic according to unit 
protocols, and were not blinded to positive/ negative fetal fibronectin result and CL 
measurement.  Cerclage was performed at discretion of the clinicians given a lack of 
established evidence for this intervention.  
 
 Repeated fFN measurements were taken on each visit to Preterm Birth Clinic.  For the 
purpose of this analysis, if there were more than two measurements, the first test obtained 
during an ‘early’ gestational age window (18+0 to 21+6), and a ‘standard’ gestational age 
window (22-27+6), was used.  For women with tests obtained during ‘early’ and ‘standard’ 
gestation age windows, both tests were included in the analysis.  If the sample was ineligible 
(e.g recent bleeding or sexual intercourse), it was excluded from analysis and the next 
available sample within the assessment window that fulfilled all criteria was used.  If no 
appropriate sample was available the woman was excluded. 
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Pregnancy outcome details were collected from handheld notes, reviewed by trained research 
midwives, and entered onto the study database as the study progressed.  Data entry was 
checked for inaccuracies contemporaneously by senior research midwives.  Women were 
considered to have the outcome of interest (sPTB) if they had spontaneous onset of labour, or 




No formal power calculation was made but sample size was pragmatically based on analysing 
all of the available data on twins during the period of recruitment to the EQUIPP Study.  
Given the higher prevalence of PTB in twins, there was a reasonable expectation that 
meaningful predictive statistics could be calculated from the expected numbers (>100) 
recruited in the available time. 
 
Statistical analysis was performed using Stata 11.2.  Descriptive characteristics were 
presented  for baseline demographics.  QfFN results were grouped into four prespecified 
incremental categories (less than 10ng/mL, 10 to 49ng/mL, 50 to 199ng/mL, greater than or 
equal to 200ng/mL) and the corresponding sPTB rates calculated for each window.  Non-
parametric trend tests for qfFN at different levels were carried out for each predefined 
gestational endpoint, and ROC areas with 95% confidence intervals (CI) were calculated. 
 
Predefined thresholds of 10ng/ml or greater, 50ng/ml or greater and 200ng/ml or greater were 
used to establish sensitivity, specificity, positive predictive value (PPV), negative predictive 
value (NPV), and likelihood ratios for prediction of sPTB by ‘early’ and ‘standard’ qfFN 
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tests before 30 completed weeks of gestation (primary outcome) and predefined outcomes of 
delivery before 34 and 37 completed weeks of gestation.  ROC areas with 95% CI were 
calculated to determine overall predictive accuracy for ‘early’  tests. 
 
The utility of CL measurement after stratification by qfFN was explored, as well as after 
stratification by the presence and absence of a short cervix (less than 25mm).  This study is 




The study was approved by the South East London Research Ethics Committee (REC no 
10/H0806/68, London, United Kingdom).  Written informed consent was obtained from all 
participants.  Gestational age was confirmed with early Obstetric Ultrasound (11-14 weeks of 
gestation).  Participant baseline demographics, obstetric history and risk factors were entered 




A consecutive series of 5497 women meeting eligibility criteria were enrolled into the 
EQUIPP study.  Of those women, 235 had a twin pregnancy, and 157 women had a valid 
qfFN test result in the pre-specified ‘early’ or ‘standard’ gestational age window.  After 
applying exclusion criteria, analysis was performed on 92% (144/157) of women.  Of those 
144 women, 101 had ‘early’ tests and 130 women had ‘standard’ tests, with 87 having both 
early and standard tests. Women with iatrogenic delivery before the prespecified gestation 
endpoint under consideration were excluded from the analysis.  (For ‘early’ tests: n=3 less 
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than 30 weeks of gestation, n=5 less than 34 weeks of gestation and n=26 less than 37 weeks 
of gestation and for ‘standard’ tests: n=4 less than 30 weeks of gestation, n=9 less than 34 
weeks of gestation and n=37 less than 37 weeks of gestation)  (See Fig. 1).  Demographic and 
obstetric characteristics for the study participants are displayed in table 1.  No adverse events 
were reported in relation to the qfFN test.   
 
The sPTB rate for our primary outcome was 9% (11/126) at less than 30 weeks of gestation. 
It was 18% (22/121) at less than 34 weeks of gestation and 51% (47/93) at less than 37 weeks 
of gestation.   
 
The proportion of women with sPTB according to fetal fibronectin concentration is shown in 
table 2.  In this cohort, 90 (71%) were in the lowest category (less than 10 ng/mL).  As qfFN 
increased so too did sPTB rate <30/40 for all gestational endpoints, increasing from 3/90 
(3.3%) in the less than 10ng/mL category to 6/8 (75%) in the greater than 200ng/mL category 
for sPTB at less than 30 weeks of gestation.  Non-parametric trend tests for fFN at different 
levels were significant (p<0.01) for our primary endpoint (30/40) but also our predefined 
gestational endpoints less than 34 and 37 weeks of gestation.  ROC curves of 0.82 (CI 0.65 to 
0.99); 0.74 (CI 0.63 to 0.86) and 0.67 (CI 0.59 to 0.76) for prediction of sPTB at less than 30, 
34 and 37 weeks of gestation respectively, demonstrate overall predictive ability of qfFN 
regardless of threshold (see figure 2 and table 2). 
 
The diagnostic accuracy of qfFN for predicting sPTB at less than 30 weeks of gestation with 
the use of prespecified thresholds of 10ng/mL, 50ng/mL and 200ng/mL is shown in table 3 
for ‘early’ and ‘standard’ tests.  For both tests, use of a higher threshold (>200ng/mL) 
considerably improved the specificity of the tests together with an improved PPV, whilst 
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retaining a high NPV. The ROC area for ‘early’ tests was 0.53 (CI 0.29 to 0.81) suggested no 
relation to gestational outcome unlike the ‘standard’ test where the ROC area of 0.82 (CI 0.65 
to 0.99) was significant (table 2). 
 
Of the cohort included in the analysis of qfFN with tests during the ‘standard’ gestational age 
window, 90% (117/130) had paired ultransonographic transvaginal CL measurements.  Table 
4 illustrates the proportion of women who delivered prematurely, stratified according to CL 
measurement and qfFN category.  Short CL was related to outcome at all gestational 
endpoints.   
 
For women with a short cervix (less than 25mm), sPTB rate at less than 30 weeks increased 
from 0% for those with low qfFN concentration less than 10ng/mL to 86% for those with 
qfFN concentration greater than or equal to 200ng/mL.   
 
Conversely, in women with a high qfFN concentration greater than 200ng/mL, but a long 
cervix greater than 25mm PPV for sPTB was 0%.  Although numbers were small, this 
suggests that combining qfFN and CL measurement strengthens prediction. 
 
Of women with tests during the ‘standard’ gestational age window, 60% (78/130) had risk 
factors for sPTB in addition to twin pregnancy, including previous sPTB (n=27), previous 
PPROM (n=9), previous late miscarriage 16+0-23+6 (n=12), previous cervical surgery (n=30).   
There was a trend towards improved prediction of sPTB for all gestational endpoints when at 
least one additional risk factor for sPTB was present.  For our primary outcome of sPTB 
ROC areas were 0.87, CI 0.80 to 0.94 versus 0.55, CI 0.22 to 0.88 for prediction of sPTB less 
than 30 weeks of gestation for women with at least one additional risk factor compared to 
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twin pregnancy as the sole risk factor.  But the difference (0.32, CI -0.07 to 0.71) was not 





To our knowledge, this is the first study to demonstrate the diagnostic accuracy of differing 
concentrations of qfFN for prediction of sPTB in high-risk asymptomatic women with twin 
pregnancies.  For example, for women with a qfFN concentration greater than or equal to 
200ng/mL, 75% delivered less than 30 weeks of gestation compared to only 3% of those with 
a qfFN concentration less than 10ng/mL.  A risk of sPTB of 3% is less than background risk 
in the general UK Obstetric population for twins.  Therefore, clinicians can use the additional 
risk information afforded by quantifying fetal fibronectin to reassure women who are in fact 
low risk based on the results of the test, even in the presence of risk factors for sPTB in 
addition to twin pregnancy. Early qfFN tests (less than 22+0 weeks of gestation) do not have 
good prediction, contrary to singleton data, and should not be relied on until further research 
can confirm or refute this. (7) 
 
Because the majority of tests (71%) are less than 10ng/mL, use of qfFN to determine discrete 
values provides a unique and new opportunity to provide reassurance to the majority of 
women who are theoretically at high risk; potentially reducing significant costs, both 
emotional and economic. 
 
Quantitative fetal fibronectin test results also were synergistic with CL testing, more 
accurately discriminating those women with a short cervix destined to deliver early from 
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those who will not; of those women with a short cervix less than 25mm none with an fFN  
less than 10ng/mL delivered before 30 weeks of gestation compared to 86% of women with 
an fFN greater than 200ng/mL.  This suggests value in combining these tests. 
 
The association between increasing cervicovaginal fFN and progressive risk has been 
demonstrated in asymptomatic singleton pregnancy (6) and is biologically plausible because 
raised fFN represents disruption of the maternal-fetal interface.  If degradation and release of 
fFN is the result of activation of matrix metalloproteinases release from immune cells 
following infection and/or inflammation, as has been hypothesized, (13) the more substantial 
the extent of infectious or inflammatory insult, the greater the release of fFN, corresponding 
with increased risk of delivery.  These mechanisms may also be important in twins. 
In twins, it has been suggested that additional factors contribute to increased risk of sPTB in 
twin pregnancy, related to uterine distension, and resultant myometrial stretch triggering 
prostaglandin release, upregulation of oxytocin receptors and increased myometrial 
contractility.  Although non-significant, there was a trend towards better predictive accuracy 
when risk factors for sPTB in addition to twin pregnancy were present.  A  recent study by 
Easter et al, where women with a previous sPTB in addition to twin pregnancy compared to 
twin pregnancy as the sole risk factor had an increased likelihood of delivery at less than 35 
weeks of gestation, (adjusted Odds Ratio 2.44, 95% CI1.28-4.66). (14)  Therefore prediction in 
this group is important.  
 
Conclusion 
It has previously been shown that the combination of CL and fFN may be useful in predicting 
women with twin pregnancy who are asymptomatic but at high risk of sPTB.  (11), (9), (15) 
However, these studies are based around qualitative, rather than quantitative fFN.  The main 
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strength of this study is that it is the first to demonstrate the predictive accuracy of qfFN in 
asymptomatic twin pregnancy. This data has been incorporated into the QUIPP App 
(www.quipp.geneticdigital.co.uk) which combines qfFN, CL measurements and a woman’s 
risk factors to calculate an individualised risk score to guide management, and now includes 
twins. Prophylactic interventions have been challenging in twins and further work is needed 
to establish linking prediction to intervention, and to evaluate qfFN for prediction of 
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Table 1.  Demographic and Obstetric Characteristics of women with twin pregnancies tested 
for cervicovaginal fluid fetal fibronectin concentrations between 18 to 21+6 (n=101) and 22 to 






















































Age (y) 33.9 ± 5.2 34 ± 5.6 
Ethnicity   
White 60 (59.4%) 81 (62.3%) 
Black 27 (26.7%) 32 (24.6%) 
Asian 8 (7.9%) 9 (6.9%) 
Other 6 (5.9%) 8 (6.2%) 
BMI (kg/m2) 26.1 ± 5.8 25.9 ± 5.6 
Smoking status   
Current 5 (5%) 6 (4.6%) 
Ex- smoker (gave 
up before 
pregnancy) 
24 (23.8%) 25 (19.2%) 
Ex-smoker (gave 
up in pregnancy) 
3 (3.0%) 4 (3.1%) 
Never  69 (68.3%) 95 (73.1%) 
Recurrent UTI 6 (5.9%) 8 (6.2%) 
Domestic violence 3 (3.5%) 2 (1.7%) 
Previous preterm 
birth 
21 (20.8%) 27 (20.8%) 
Previous PPROM 11 (10.9%) 9 (6.9%) 
Previous late 
miscarriage 
11 (10.9%) 12 (9.2%) 
Previous cervical 
surgery 




7 (6.9%) 14 (10.8%) 
Cervical cerclage in 
current pregnancy 
7 (6.9%) 10 (7.7%) 
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Table 2: Spontaneous Preterm Birth in Asymptomatic High-Risk Women according to 
Quantitative Cervicovaginal Fluid Fetal Fibronectin Categories for standard (22 to 27+6 
weeks of gestation) test period. 
 
qfFN, quantitative cervicovaginal fluid fetal fibronectin.  Data are n (%) unless otherwise 
specififed.  Non-parametric trend tests for fFN at different levels (<10, 10-49, 50-199, >200) 
for predicting delivery at <30, <34, <37 weeks of gestation are all significant, p<0.01. 
(*Women with iatrogenic deliveries before the gestation of analysis were excluded; see ‘All’ 
qfFN categories: n=4 at less than 30 weeks of gestation, n=9 at less than 34 weeks of 
gestation and n=37 at less than 37 weeks of gestation, which is reflected in the denominator 























 Spontaneous Preterm Birth (weeks of 
gestation)* 
qfFN Category (ng/ml) n (%) Less than 30 Less than 34 Less than 37 
< 10 90 (71.4) 3/90 (3.3) 8/85 (9.4) 25/64 (39.1) 
10-49 21 (16.6) 0/21 (0) 4/21 (19) 9/15 (60) 
50-199 7 (5.5) 2/7 (28.6) 3/7 (42.9) 5/6 (83.3) 
>200 8 (6.3) 6/8 (75) 7/8 (87.5) 8/8 (100) 
All 126 (100) 11/126 (8.7) 22/121 
(18.2) 
47/93 (50.5) 







Table 3: Prediction of Spontaneous Preterm Birth at less than 30 weeks of gestation 
According to Cervicovaginal Fluid Fetal Fibronectin concentration early (18 to 21+6) and 
standard test (22 to 27+6). 
 
PPV, positive predictive value; NPV negative predictive value; LR, likelihood ratio.  Data are 



























 Fetal Fibronectin Threshold (ng/Ml) 
Predictive 
variable 
10 or greater 50 or greater 200 or greater 
Early Standard Early Standard Early Standard 














































Positive LR 1.6 (0.69-
3.7) 





















Table 4. Proportion of women with Spontaneous Preterm Birth when analysed according to 
cervical length measurement (above and below 25mm) and Quantitative Cervicovaginal 
Fluid Fetal Fibronectin category measured between 22 to 27+6 weeks of gestation. (*Women 
with iatrogenic deliveries were excluded, which is reflected in the denominator changing at 
each gestational endpoint). 
 






n (%) Less than 30 Less than 34 Less than 37 
Cervix 25mm or greater 
QfFN < 10 73 (80.2) 3/73 (4.1) 6/70 (8.6) 20/58 (34.5) 
QfFN 10-199 17 (18.7) 0/17 (0) 1/17 (5.8) 7/13 (53.8) 
QfFN >200 1 (1.1) 0/1 (0) 0/1 (0) 1/1 (100) 
Total 91 (100) 3/91 (3.3) 7/88 (8) 28/72 (38.9) 
Cervix less than 25mm 
QfFN less than 
10 
10 (38.5) 0/10 (0) 1/9 (11.1) 4/4 (100) 
QfFN 10-199 9 (34.6) 2/9 (22) 6/9 (67) 6/7 (86) 
QfFN >200 7 (26.9) 6/7 (85.7) 7/7 (100) 7/7 (100) 
Total 26 (100) 8/26 (30.8) 14/25 (56) 17/18 (94.4) 
 
 
 
 
 
 
 
